For adults with chronic kidney disease (CKD), FARXIGA is a prescription medicine approved to reduce the risk of further worsening of kidney disease, end-stage kidney disease, death due to cardiovascular disease, and hospitalization for heart failure. See more.

CHRONIC KIDNEY DISEASE

INTRODUCING A BREAKTHROUGH IN MANAGING CKD

CKD Hero
CKD Hero

The wait is over

If you have chronic kidney disease (CKD), you’re probably thinking about how essential your kidneys are. You’ve got your future in mind and are taking steps to slow the progression toward end-stage kidney disease, which could mean dialysis or a kidney transplant. But what if there were a medicine that may help you reach your goals? Now there’s a new option to consider.

Discover the FARXIGA difference

What the FDA is saying

The Food and Drug Administration granted FARXIGA its “Breakthrough Therapy Designation” for its review in chronic kidney disease. That means it may provide substantial improvement over treatments that are currently available for the treatment of CKD.

What this may mean for you

With FARXIGA, you could keep living life by reducing the serious risks of CKD, including death due to cardiovascular disease. This is true whether or not you have type 2 diabetes.

FIRST CKD TREATMENT APPROVED IN 20 YEARS FOR PATIENTS WITH AND WITHOUT TYPE 2 DIABETES

HELPS YOU KEEP LIVINGBY REDUCING THE RISK OF CV DEATH

First approved CKD treatment in decades for patients with and without type 2 diabetes, FARXIGA is proven to help by:

CKD Progression Caution Icon

Slowing the
progression of CKD

Progression towards end stage kidney disease

Reducing the risk of end-stage kidney disease, which can lead to dialysis

Keeping you living life

Keeping you living life by reducing the risk of
CV death

For people being treated with CKD:

Talk to your doctor about how FARXIGA may help your CKD.

Get 3 key questions

 
FARXIGA® (dapagliflozin) Co-pay Card
FARXIGA® (dapagliflozin) Co-pay Card
IMPORTANT SAFETY INFORMATION